Trailing Twelve Months Revenue Growth: Bionomics Limited (BNOX)

Brandmark of bionomics.com.au (BNOX)

The minimal environmental footprint of Bionomics Limited (BNOX) does not impact its share price; consequently, the TTM annual revenue growth reflects a metric level of -91.60. The asset's price action relies on the independence of neuropharmaceuticals from economic cycles. However, potential clinical trial failures and an acute need for continuous external financing due to the lack of commercial products pose a serious threat.

Bionomics (BNOX): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 02/20/2024

bionomics.com.au (BNOX) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Bionomics Limited
Manufactured products of Bionomics Limited

This indicator measures the percentage change in revenue over the trailing twelve months, allowing for an assessment of the business's fundamental stability and the pace of its market share expansion. By analyzing the year-over-year (LTM) gross revenue dynamics on the GURU.Markets platform, Bionomics Limited (BNOX) investors can confirm the effectiveness of the biopharmaceutical licensing model, where growth in royalty income against fixed R&D costs ensures high profit scalability.